Tena Vivó Glòria, Cunillera Puértolas Oriol, Albareda Riera Mercè, Parellada Esquius Neus, Isidro Albaladejo Mònica, Rodríguez Palomar Gemma, Palmero Aliste Silvia, Vila Lluís
Hospital de Viladecans, Obstetrics and Gynecology Viladecans, Barcelona, Spain.
Unitat de Suport a la Recerca Metropolitana Sud, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, l'Hospitalet de Llobregat, Catalunya, Spain.
Front Endocrinol (Lausanne). 2025 Mar 18;16:1445977. doi: 10.3389/fendo.2025.1445977. eCollection 2025.
This study aims to describe hypothyroidism monitoring and control during the first trimester of pregnancy in women with known hypothyroidism in Catalonia.
Pregnancies registered in primary care in Catalonia between 2014 and 2016 were retrospectively studied. Women with hypothyroidism were selected for the study. Hypothyroidism was defined if, on the date of the last menstrual period (LMP), there was an updated thyroid hormone prescription (code ATC H03AA -levothyroxine) or any of the following active diagnostic codes: ICD-10: E02, E03, E89.0. To evaluate hypothyroidism monitoring and control, thyrotropin (TSH) tests during the first trimester of pregnancy were considered and categorized according to the reference values of each laboratory.
Out of 111,811 pregnancies, 5,574 had known hypothyroidism. TSH was evaluated in 3,158 (56.65%) of them. The TSH values were within the recommended ranges in 1,146 (36.3%) of the cases, being low abnormal in 53 of them (1.7%) and high abnormal in 1,959 (62%).
TSH testing was not evaluated in almost half of the pregnant women with known hypothyroidism in primary care services in Catalonia during the pregnancy first trimester. Among those tested, more than two-thirds had TSH levels outside the target range. This means that it is essential to improve the management of hypothyroidism during the first trimester of pregnancy in Catalonia.
本研究旨在描述加泰罗尼亚已知甲状腺功能减退症的女性在妊娠早期的甲状腺功能减退症监测与控制情况。
对2014年至2016年在加泰罗尼亚初级保健机构登记的妊娠情况进行回顾性研究。选择患有甲状腺功能减退症的女性进行研究。如果在末次月经日期（LMP）有最新的甲状腺激素处方（ATC编码H03AA - 左甲状腺素）或任何以下现行诊断编码，则定义为甲状腺功能减退症：ICD - 10：E02、E03、E89.0。为评估甲状腺功能减退症的监测与控制情况，考虑妊娠早期的促甲状腺激素（TSH）检测，并根据各实验室的参考值进行分类。
在111,811例妊娠中，5,574例已知患有甲状腺功能减退症。其中3,158例（56.65%）进行了TSH评估。1,146例（36.3%）的TSH值在推荐范围内，其中53例（1.7%）为低异常，1,959例（62%）为高异常。
在加泰罗尼亚的初级保健服务中，近一半已知患有甲状腺功能减退症的孕妇在妊娠早期未进行TSH检测。在接受检测的孕妇中，超过三分之二的TSH水平超出目标范围。这意味着在加泰罗尼亚改善妊娠早期甲状腺功能减退症的管理至关重要。
